ES2176523T3 - Procedimiento para la deteccion de la enfermedad de alzheimer. - Google Patents

Procedimiento para la deteccion de la enfermedad de alzheimer.

Info

Publication number
ES2176523T3
ES2176523T3 ES96944954T ES96944954T ES2176523T3 ES 2176523 T3 ES2176523 T3 ES 2176523T3 ES 96944954 T ES96944954 T ES 96944954T ES 96944954 T ES96944954 T ES 96944954T ES 2176523 T3 ES2176523 T3 ES 2176523T3
Authority
ES
Spain
Prior art keywords
alzheimer
disease
detection
procedure
band
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96944954T
Other languages
English (en)
Inventor
Marguerite M B Kay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Corp Technologies Inc
Original Assignee
Research Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Corp Technologies Inc filed Critical Research Corp Technologies Inc
Application granted granted Critical
Publication of ES2176523T3 publication Critical patent/ES2176523T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A METODOS DE DETECCION DE LA ENFERMEDAD DE ALZHEIMER. EN CONCRETO, LA PRESENTE INVENCION PROPORCIONA ANTICUERPOS PARA LA PROTEINA DE LA BANDA 3 CAPACES DE DIFERENCIAR EL TEJIDO AFECTADO CON LA ENFERMEDAD DE ALZHEIMER DEL TEJIDO NORMAL. ADEMAS, LA INVENCION PROPORCIONA UN METODO PARA LA DETECCION DE LA ENFERMEDAD DE ALZHEIMER QUE COMPRENDE LA DETERMINACION DIFERENCIAL DE FOSFORILACION DE LA BANDA 3.
ES96944954T 1996-01-19 1996-12-13 Procedimiento para la deteccion de la enfermedad de alzheimer. Expired - Lifetime ES2176523T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1025096P 1996-01-19 1996-01-19

Publications (1)

Publication Number Publication Date
ES2176523T3 true ES2176523T3 (es) 2002-12-01

Family

ID=21744819

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96944954T Expired - Lifetime ES2176523T3 (es) 1996-01-19 1996-12-13 Procedimiento para la deteccion de la enfermedad de alzheimer.

Country Status (7)

Country Link
EP (1) EP0877939B1 (es)
JP (1) JP2000503391A (es)
AT (1) ATE219247T1 (es)
CA (1) CA2242343A1 (es)
DE (1) DE69621837T2 (es)
ES (1) ES2176523T3 (es)
WO (1) WO1997026537A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1301730A (zh) * 1999-12-24 2001-07-04 上海博德基因开发有限公司 一种新的多肽——阴离子交换蛋白9和编码这种多肽的多核苷酸
CN1301720A (zh) * 1999-12-27 2001-07-04 上海博德基因开发有限公司 一种新的多肽——阴离子交换蛋白9和编码这种多肽的多核苷酸
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
US9588129B2 (en) 2013-03-15 2017-03-07 Amira Medical Technologies Inc. Methods for analyzing blood to detect diseases associated with abnormal protein aggregation

Also Published As

Publication number Publication date
EP0877939A1 (en) 1998-11-18
WO1997026537A1 (en) 1997-07-24
JP2000503391A (ja) 2000-03-21
CA2242343A1 (en) 1997-07-24
DE69621837T2 (de) 2002-11-28
EP0877939B1 (en) 2002-06-12
DE69621837D1 (de) 2002-07-18
ATE219247T1 (de) 2002-06-15

Similar Documents

Publication Publication Date Title
HN1997000072A (es) Procedimiento para la preparacion de sildenafil
EA199800946A1 (ru) Концентрированный препарат антител
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
BR0016022A (pt) Vacina para a prevenção e tratamento da doença de alzheimer e doenças relacionadas ao amilóide
ES2128362T3 (es) Fragmentos de proteinas de prion.
DE69129302D1 (de) Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen
ATE178907T1 (de) Rezeptorbindende region des diphtherietoxius
ES2060310T3 (es) Utilizacion de la n-miristoil-(s)-fenilalanina para la obtencion de medicamentos destinados al tratamiento de enfermedades que hacen intervenir la miristoilacion.
AR003989A1 (es) Composicion cosmetica o farmaceutica y procedimiento de tratamiento cosmetico, excluido tdo tratamiento terapeutico que utiliza la composicion cosmetica.
ES2065303T5 (es) Procedimiento de diagnosis y vacuna especifica.
MX2021009975A (es) Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer.
ES2134797T3 (es) Peptidos y fragmentos de peptidos terapeuticamente utiles.
ES2227527T3 (es) Un factor de crecimiento de queratinocitos (kgf) truncado que tiene actividad biologica aumentada.
BR0114059A (pt) Derivados de resorcinol
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
ES2176523T3 (es) Procedimiento para la deteccion de la enfermedad de alzheimer.
ES2189992T3 (es) Reduccion del crecimiento del pelo.
EP0350690A3 (de) Neutralisation der in vitro- und in vivo-toxischen Eigenschaften von TNF-alfa durch monoklonale Antikörper und die davon abgeleiteten Fragmente
ATE11547T1 (de) Neue d-homosteroide, ihre verwendung und herstellung, sowie pharmazeutische praeparate damit.
SE8403630D0 (sv) Humana proteiner
HN1997000127A (es) Procedimiento e intermedios para preparar derivados de cromanol sustituidos.
BR0109164A (pt) Anticorpos monoclonais para o receptor humano para ldl, produção e uso dos mesmos
ES2140175T3 (es) Utilizacion de la monoetanolamina para preparar una composicion destinada para determinar los cueros cabelludos sensibles.
ES2053712T3 (es) Un antigeno proteico reactivo y fragmentos del mismo.